Use of low-molecular-weight heparin in percutaneous intervention

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. C, 2000, Pages

  Curran, Michael J ^a   Grines, Cindy L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; CORONARY ARTERY OBSTRUCTION; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART CATHETERIZATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIOGRAPHY; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0002378337     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Waller BF, Gurfinkel HJ, Rogers FJ, et al. Early and late morphologic changes in major epicardial coronary arteries after percutaneous coronary angioplasty. Am J Cardiol 1984;53:42C-47C.
2. Honye J, Mahon DJ, Jain A, et al. Morphological effects of coronary balloon angioplasty in vivo assessed by intravascular ultrasound imaging. Circulation 1992;85:1012-1025.
3. Popma JJ, Weitz J, Bittl JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998;114:728S-741S.
4. Laskey MAL, Deutsch E, Barnathan E, et al. Influence of heparin therapy on percutaneous transluminal angioplasty outcome in unstable angina pectoris. Am J Cardiol 1990;65:1425-1429.
5. Laskey MAL, Deutsch E, Hirschfield JW, et al. Influence of heparin therapy on percutaneous coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990;65:179-182.
6. Friedman HZ, Cragg DR, Glazier SM, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994;24:1214-1219.
7. Ellis SG, Roubin GS, Wilentz J, et al. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-782.
8. Rabah M, Mason D, Muller DA, et al. Heparin after percutaneous intervention (HAPI): A prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. J Am Coll Cardiol 1999;34:461-467.
9. Dougherty KG, Gaos CM, Bush HS, et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diag 1992;21:260-263.
10. Bittl JA. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty: The Hirulog Angioplasty Study Investigators. Am Heart J 1995;130:658-665.
11. Narins CR, Hillegass WB, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
12. Koch KT, Piek JJ, deWinter RJ, et al. Safety of low dose heparin in elective coronary angioplasty. Heart 1997;77:517-522.
13. Weitz JI. Low molecular-weight heparins. N Engl J Med 1997;337:688-698.
14. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
15. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin in patients with unstable coronary artery disease. N Engl J Med 1997;337:447-452.
16. Grines CL. Anticoagulation requirements for coronary interventions and the role of low molecular weight heparins. J Invas Cardiol 1999;11(Suppl A):7A-12A.